
Altitude Life Science Ventures
1014 Market St. Suite 200, Kirkland, WA, 98033, United States
Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Ansa Biotechnologies | Oct 2025Participated | $54 MSeries B | |
Lila Sciences | Sep 2025Participated | $235 MSeries A | |
Lila Sciences | Mar 2025Participated | $200 MSeed | |
Vilya | Jun 2024Participated | $71 MSeries A | |
Mozart Therapeutics | Jun 2023Participated | $25 MSeries A | |
Ring Therapeutics | Mar 2023Led | $87 MSeries C | |
Escient Pharmaceuticals | Nov 2022Participated | $120 MSeries C | |
Neumora Therapeutics | Oct 2022Participated | $112 MSeries B | |
Tessera Therapeutics | Apr 2022Participated | $300 MSeries C | |
Ansa Biotechnologies | Apr 2022Participated | $68 MSeries A | |
Generate Biomedicines | Nov 2021Participated | $370 MSeries B | |
Mozart Therapeutics | Oct 2021Participated | $55 MSeries A | |
Ansa Biotechnologies | Oct 2025Participated | $54 MSeries B | |
Lila Sciences | Sep 2025Participated | $235 MSeries A | |
Lila Sciences | Mar 2025Participated | $200 MSeed | |
Vilya | Jun 2024Participated | $71 MSeries A | |
Mozart Therapeutics | Jun 2023Participated | $25 MSeries A | |
Ring Therapeutics | Mar 2023Led | $87 MSeries C | |
Escient Pharmaceuticals | Nov 2022Participated | $120 MSeries C | |
Neumora Therapeutics | Oct 2022Participated | $112 MSeries B | |
Tessera Therapeutics | Apr 2022Participated | $300 MSeries C | |
Ansa Biotechnologies | Apr 2022Participated | $68 MSeries A | |
Generate Biomedicines | Nov 2021Participated | $370 MSeries B | |
Mozart Therapeutics | Oct 2021Participated | $55 MSeries A |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 0 | 1 |
| Series A | 0 | 12 |
| Series B | 1 | 13 |
| Series C+ | 1 | 8 |
| Other Equity | 0 | 1 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Nov '09 | 1 |
| Dec '09 | 0 |
| Jan '10 | 0 |
| Feb '10 | 0 |
| Mar '10 | 0 |
| Apr '10 | 0 |
| May '10 | 0 |
| Jun '10 | 1 |
| Jul '10 | 0 |
| Aug '10 | 0 |
| Sep '10 | 0 |
| Oct '10 | 1 |
| Nov '10 | 0 |
| Dec '10 | 0 |
| Jan '11 | 0 |
| Feb '11 | 0 |
| Mar '11 | 0 |
| Apr '11 | 0 |
| May '11 | 0 |
| Jun '11 | 1 |
| Jul '11 | 0 |
| Aug '11 | 0 |
| Sep '11 | 2 |
| Oct '11 | 0 |
| Nov '11 | 0 |
| Dec '11 | 0 |
| Jan '12 | 0 |
| Feb '12 | 0 |
| Mar '12 | 0 |
| Apr '12 | 0 |
| May '12 | 0 |
| Jun '12 | 0 |
| Jul '12 | 0 |
| Aug '12 | 0 |
| Sep '12 | 0 |
| Oct '12 | 0 |
| Nov '12 | 0 |
| Dec '12 | 0 |
| Jan '13 | 0 |
| Feb '13 | 0 |
| Mar '13 | 0 |
| Apr '13 | 0 |
| May '13 | 0 |
| Jun '13 | 0 |
| Jul '13 | 0 |
| Aug '13 | 0 |
| Sep '13 | 0 |
| Oct '13 | 0 |
| Nov '13 | 0 |
| Dec '13 | 0 |
| Jan '14 | 0 |
| Feb '14 | 0 |
| Mar '14 | 0 |
| Apr '14 | 0 |
| May '14 | 0 |
| Jun '14 | 0 |
| Jul '14 | 0 |
| Aug '14 | 0 |
| Sep '14 | 0 |
| Oct '14 | 0 |
| Nov '14 | 0 |
| Dec '14 | 0 |
| Jan '15 | 0 |
| Feb '15 | 0 |
| Mar '15 | 0 |
| Apr '15 | 0 |
| May '15 | 0 |
| Jun '15 | 0 |
| Jul '15 | 0 |
| Aug '15 | 0 |
| Sep '15 | 0 |
| Oct '15 | 0 |
| Nov '15 | 0 |
| Dec '15 | 0 |
| Jan '16 | 1 |
| Feb '16 | 0 |
| Mar '16 | 0 |
| Apr '16 | 1 |
| May '16 | 0 |
| Jun '16 | 0 |
| Jul '16 | 1 |
| Aug '16 | 0 |
| Sep '16 | 0 |
| Oct '16 | 1 |
| Nov '16 | 0 |
| Dec '16 | 0 |
| Jan '17 | 0 |
| Feb '17 | 0 |
| Mar '17 | 0 |
| Apr '17 | 1 |
| May '17 | 0 |
| Jun '17 | 0 |
| Jul '17 | 0 |
| Aug '17 | 0 |
| Sep '17 | 0 |
| Oct '17 | 0 |
| Nov '17 | 0 |
| Dec '17 | 0 |
| Jan '18 | 0 |
| Feb '18 | 0 |
| Mar '18 | 1 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 1 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 0 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 0 |
| Feb '19 | 0 |
| Mar '19 | 1 |
| Apr '19 | 1 |
| May '19 | 0 |
| Jun '19 | 2 |
| Jul '19 | 0 |
| Aug '19 | 0 |
| Sep '19 | 0 |
| Oct '19 | 1 |
| Nov '19 | 0 |
| Dec '19 | 0 |
| Jan '20 | 1 |
| Feb '20 | 0 |
| Mar '20 | 1 |
| Apr '20 | 0 |
| May '20 | 0 |
| Jun '20 | 1 |
| Jul '20 | 0 |
| Aug '20 | 0 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 2 |
| Feb '21 | 0 |
| Mar '21 | 0 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 1 |
| Aug '21 | 0 |
| Sep '21 | 0 |
| Oct '21 | 2 |
| Nov '21 | 1 |
| Dec '21 | 0 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 2 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 1 |
| Nov '22 | 1 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 1 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 1 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 1 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 1 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 1 |
| Oct '25 | 1 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 36 |
| AI & Machine Learning | 5 |
| Space & Frontier Tech | 5 |
| Clean Energy & Sustainability | 2 |
| Consumer & Lifestyle | 2 |
| Hardware & Robotics | 1 |
| Manufacturing | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 6 |
| $25M-$50M | 6 |
| $50M-$100M | 12 |
| $100M-$250M | 9 |
| $250M-$500M | 3 |
| $500M-$1B | 1 |
| $1B+ | 0 |
Deals By Geography
Top 1 of 1 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 37 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| ARCH Venture Partners | 23 |
| Alexandria Venture Investments | 10 |
| Flagship Pioneering | 8 |
| Invus | 6 |
| Partner Fund Management | 5 |
| Alaska Permanent Fund | 4 |
| F-Prime Capital | 4 |
| Mubadala Capital | 4 |
| Omega Funds | 4 |
| T. Rowe Price Associates | 4 |
| Venrock | 4 |
| Abu Dhabi Investment Authority | 3 |
| Alloy Ventures | 3 |
| Biomatics Capital | 3 |
| Fidelity Management & Research Company | 3 |
| Google Ventures | 3 |
| Lux Capital | 3 |
| March Capital | 3 |
| Osage University Partners | 3 |
| Polaris Partners | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 2 | 5% |
| Participating | 35 | 95% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 0 | 0% |
| Co-led | 2 | 100% |
Team
Co-Founder and Partner